Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs

48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received one observation in the Form-483